# US 2026/0131018 A1 · Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0131018 A1
- Document ID: US20260131018A1
- Status: Published application
- Kind: A1
- Application number: 19/426,722
- Filed: 2025-12-19
- Published: 2026-05-14
- Earliest claimed: 2021-08-11
- Assignees: ImmunityBio, Inc.
- Applicants: ImmunityBio, Inc.
- Inventors: Hing C. Wong; Xiaoyun Zhu; Pallavi Chaturvedi; Varghese George; Niraj Shrestha; Michael Dee
- Web page: https://patentgrep.com/patent/US20260131018A1

## CPC

- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 47/641: {Branched, dendritic or hypercomb peptides}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases.

## Claims

### Claim at position 1

1-61. (canceled)

### Claim 62

A method of reducing inflammation in a liver of a subject having type 2 diabetes, wherein the method comprises administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4;
(ii) soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:1; and
(iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:18;
(b) a second chimeric polypeptide comprising:
(i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:16; and
(ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4,
wherein:
the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains; and
the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.

### Claim 63 (depends on 62)

The method of claim 62, wherein the first chimeric polypeptide further comprises one or more additional target-binding domain(s).

### Claim 64 (depends on 62)

The method of claim 62, wherein the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:6.

### Claim 65 (depends on 62)

The method of claim 62, wherein the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:5.

### Claim 66 (depends on 62)

The method of claim 62, wherein the administering results in a decrease in the expression of one or more genes in the liver of the subject selected from the group consisting of: ACSS1, RETN, SLC2A4, PDK4, PNPLA3, GADD45B, PPARGC1A, CAV1, ENDOD1, REG3G, IGHG3, IGHG2B, SCGB3A1, GLYCAM1, IGHG2C, IGKC, LTF, MS4A1, JCHAIN, CD19, IGHM, IFI27L2A, ACKR3, LSP1, PMEPA1, CORO1A, GPX3, MYH8, NPPA, TCAP, FLNC, SLC36A2, MYH6, ACTC1, ACTA2, and TPM2, as compared to the level of expression of the one or more genes in the subject prior to the administering.

### Claim 67 (depends on 62)

The method of claim 62, wherein the administering results in an increase in the expression of one or more genes in the liver of the subject selected from the group consisting of: SLC34A2, and CISH, as compared to the level of expression of the one or more genes in the subject prior to the administering.

### Claim 68

A method of decreasing hepatocytic senescence in a liver of a subject having type 2 diabetes, wherein the method comprises administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4;
(ii) soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:1; and
(iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:18;
(b) a second chimeric polypeptide comprising:
(i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:16; and
(ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4,
wherein:
the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains; and
the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.

### Claim 69 (depends on 68)

The method of claim 68, wherein the first chimeric polypeptide further comprises one or more additional target-binding domain(s).

### Claim 70 (depends on 68)

The method of claim 68, wherein the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:6.

### Claim 71 (depends on 68)

The method of claim 68, wherein the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:5.

### Claim 72 (depends on 68)

The method of claim 68, wherein the administering results in a decrease in the expression of one or more genes in the liver of the subject selected from the group consisting of: ACSS1, RETN, SLC2A4, PDK4, PNPLA3, GADD45B, PPARGC1A, CAV1, ENDOD1, REG3G, IGHG3, IGHG2B, SCGB3A1, GLYCAM1, IGHG2C, IGKC, LTF, MS4A1, JCHAIN, CD19, IGHM, IFI27L2A, ACKR3, LSP1, PMEPA1, CORO1A, GPX3, MYH8, NPPA, TCAP, FLNC, SLC36A2, MYH6, ACTC1, ACTA2, and TPM2, as compared to the level of expression of the one or more genes in the subject prior to the administering.

### Claim 73 (depends on 68)

The method of claim 68, wherein the administering results in an increase in the expression of one or more genes in the liver of the subject selected from the group consisting of: SLC34A2, and CISH, as compared to the level of expression of the one or more genes in the subject prior to the administering.

### Claim 74

A method of rebalancing metabolic function in a liver of a subject having type 2 diabetes, wherein the method comprises administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
(a) a first chimeric polypeptide comprising:
(i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4;
(ii) soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:1; and
(iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:18;
(b) a second chimeric polypeptide comprising:
(i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:16; and
(ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4,
wherein:
the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains; and
the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.

### Claim 75 (depends on 74)

The method of claim 74, wherein the first chimeric polypeptide further comprises one or more additional target-binding domain(s).

### Claim 76 (depends on 74)

The method of claim 74, wherein the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:6.

### Claim 77 (depends on 74)

The method of claim 74, wherein the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO:5.

### Claim 78 (depends on 74)

The method of claim 74, wherein the administering results in a decrease in the expression of one or more genes in the liver of the subject selected from the group consisting of: ACSS1, RETN, SLC2A4, PDK4, PNPLA3, GADD45B, PPARGC1A, CAV1, ENDOD1, REG3G, IGHG3, IGHG2B, SCGB3A1, GLYCAM1, IGHG2C, IGKC, LTF, MS4A1, JCHAIN, CD19, IGHM, IFI27L2A, ACKR3, LSP1, PMEPA1, CORO1A, GPX3, MYH8, NPPA, TCAP, FLNC, SLC36A2, MYH6, ACTC1, ACTA2, and TPM2, as compared to the level of expression of the one or more genes in the subject prior to the administering.

### Claim 79 (depends on 74)

The method of claim 74, wherein the administering results in an increase in the expression of one or more genes in the liver of the subject selected from the group consisting of: SLC34A2, and CISH, as compared to the level of expression of the one or more genes in the subject prior to the administering.
